Waldenstrom's Macroglobulinemia This is an OPML file. It can be used to export all the MedWorm RSS feeds on this topic into your personal RSS reader (usually you have to save this file to your own computer before clicking on an Import OPML command in your own feed reader to upload the file which will then import all the feeds) or it can be used by webmasters to integrate MedWorm feeds with their own website. This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.
Find the best Christmas presents and January Sales in the UK with this simple shopping directory.
This page shows you the latest news and research items in this category.
Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia
Key Points Presents the data from a phase 2 clinical trial of panobinostat in patients with relapsed WM. Establishes a role for histone deacetylase inhibitors as an active class of therapeutic agents in WM. (Source: Blood)
Source: Blood - February 21, 2013 Category: Hematology Authors: Ghobrial, I. M., Campigotto, F., Murphy, T. J., Boswell, E. N., Banwait, R., Azab, F., Chuma, S., Kunsman, J., Donovan, A., Masood, F., Warren, D., Rodig, S., Anderson, K. C., Richardson, P. G., Weller, E., Matous, J. Tags: Free Research Articles, Lymphoid Neoplasia, Clinical Trials and Observations Source Type: research
FDA grants 'Breakthrough Therapy Designation' to ibrutinib for treatment of relapsed or refractory mantle cell lymphoma and Waldenstrom's macroglobulinemia
Source: BioSpace , PharmaTimes Area: News The FDA has granted 'Breakthrough Therapy Designation' to ibrutinib (as monotherapy) for the treatment of patients with relapsed or refractory mantle cell lymphoma (MCL) and for the treatment of patients with Waldenstrom's macroglobulinemia (WM). Ibrutinib is an investigational oral agent designed to specifically target and selectively inhibit an enzyme called Bruton's tyrosine kinase (BTK), a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel regulating apoptosis, adhesion, and cell migration and homing. The Breakthr...
Source: NeLM - News - February 14, 2013 Category: Drugs & Pharmacology Source Type: news
Waldenstrom macroglobulinemia presenting with pancreatic mass: a case report and review of literature.
CONCLUSION: To our knowledge this is the first report of a patient with Waldenstrom macroglobulinemia presenting with a pancreatic mass adding to the spectrum of clinical presentations seen in this disease. This adds to the wide variety of gastrointestinal related clinical presentations of Waldenstrom macroglobulinemia and points to the need for considering Waldenstrom macroglobulinemia along with other lymphoid neoplasms in the differential diagnosis of pancreatic lesions. PMID: 23306344 [PubMed - in process] (Source: JOP)
Source: JOP - February 1, 2013 Category: Gastroenterology Authors: Nayak HK, Kar P, Bagchi A, Kapoor N, Kapahtia S, Sonika U, Kumar N, Kumar S Tags: JOP Source Type: research
Nuclear protein dysregulation in lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia.
In this study, the expression patterns of PAX5/BSAP, MUM1/IRF4, and PRDM1/BLIMP1 were analyzed in plasma cells and lymphocytes in 29 cases of newly diagnosed LPL/WM by double immunohistochemical staining with CD138 and CD22. These patterns were compared with the expression profiles seen in normal bone marrow samples, reactive tonsils, and cases of plasma cell myeloma and marginal zone lymphoma. The median percentage of plasma cells coexpressing CD138 and PAX5 was significantly higher in LPL/WM compared with benign tissues (P = .001), marginal zone lymphoma (P = .002), and plasma cell myeloma (P < .0001), whereas the med...
Source: American Journal of Clinical Pathology - February 1, 2013 Category: Pathology Authors: Roberts MJ, Chadburn A, Ma S, Hyjek E, Peterson LC Tags: Am J Clin Pathol Source Type: research
Immunohistochemical Detection of Hairy Cell Leukemia in Paraffin Sections Using a Highly Effective CD103 Rabbit Monoclonal Antibody.
This study is the first to describe the successful use of a CD103 antibody to identify HCL and HCL-variant in paraffin sections of formalin- or Bouin solution- fixed specimens (n = 68) using an immunoperoxidase technique. In other B-cell lymphoproliferative disorders that morphologically may resemble HCL, including chronic lymphocytic leukemia/small lymphocytic lymphoma (n = 32), mantle cell lymphoma (n = 23), lymphoplasmacytic lymphoma (n = 27), follicular lymphoma (n = 7), and marginal zone lymphoma (n = 13), lymphoid cells are nonreactive for CD103. In HCL, the CD103 staining pattern is predominantly membranous with del...
Source: American Journal of Clinical Pathology - February 1, 2013 Category: Pathology Authors: Morgan EA, Yu H, Pinkus JL, Pinkus GS Tags: Am J Clin Pathol Source Type: research
Choice of Therapy for Patients With Waldenstrom Macroglobulinemia [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - January 18, 2013 Category: Cancer & Oncology Authors: Ghobrial Tags: Chemotherapy EDITORIALS Source Type: research
Results of a Randomized Trial of Chlorambucil Versus Fludarabine for Patients With Untreated Waldenstrom Macroglobulinemia, Marginal Zone Lymphoma, or Lymphoplasmacytic Lymphoma [Hematologic Malignancies]
Conclusion In the complete intent-to-treat study population, fludarabine significantly improved PFS compared with chlorambucil, and in patients with WM, it improved OS. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - January 18, 2013 Category: Cancer & Oncology Authors: Leblond, Johnson, Chevret, Copplestone, Rule, Tournilhac, Seymour, Patmore, Wright, Morel, Dilhuydy, Willoughby, Dartigeas, Malphettes, Royer, Ewings, Pratt, Lejeune, Nguyen-Khac, Choquet, Owen Tags: Chemotherapy Hematologic Malignancies Source Type: research
Burkitt Lymphoma Arising From Lymphoplasmacytic Lymphoma Following Acquisition of MYC Translocation and Loss of the ETV6 Tumor Suppressor Gene.
We report the case of a 70-year-old woman with a 9-year history of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia who presented with rapid enlargement of a left neck mass and pancytopenia, which was diagnosed as Burkitt lymphoma with extensive bone marrow involvement. A series of histopathologic, molecular, and cytogenetic evaluations proved a cytogenetic evolution including t(8;14)(q24;q32)/MYC-IgH and identical clonal B-cell gene rearrangements from the 2 distinct lymphomas, confirming stage 4 aggressive Burkitt lymphoma arising from lymphoplasmacytic lymphoma. PMID: 23276184 [PubMed - in process] (Source:...
Source: Archives of Pathology and Laboratory Medicine - January 1, 2013 Category: Laboratory Medicine Authors: Peker D, Quigley B, Qin D, Papenhausen P, Zhang L Tags: Arch Pathol Lab Med Source Type: research
Membranoproliferative glomerulonephritis complicating Waldenstrom s macroglobulinemia
Conclusion: The presence of MPGN with prominent hyaline thrombi in the context of Waldenstrom s macroglobulinemia is uncommon and can be oligosymptomatic. We discuss this case in the context of previous literature and classifications suggested for monoclonal Ig-related renal pathologies. (Source: BMC Nephrology)
Source: BMC Nephrology - December 21, 2012 Category: Urology & Nephrology Authors: David KratochvilKerstin AmannHeike BruckMaike Büttner Source Type: research
Membranoproliferative glomerulonephritis complicating Waldenström¿s macroglobulinemia
Conclusion: The presence of MPGN with prominent hyaline thrombi in the context of Waldenström’s macroglobulinemia is uncommon and can be oligosymptomatic. We discuss this case in the context of previous literature and classifications suggested for monoclonal Ig-related renal pathologies. (Source: BMC Nephrology)
Source: BMC Nephrology - December 21, 2012 Category: Urology & Nephrology Authors: David KratochvilKerstin AmannHeike BruckMaike Büttner Source Type: research
Chlorambucil versus fludarabine for first-line treatment of Waldenstrom Macroglobulinaemia
Source: Journal of Clinical Oncology Area: News According to the results of a randomised, controlled trial, fludarabine is associated with a similar overall response rate (ORR) to chlorambucil when used in the first-line treatment of Waldenstrom macroglobulinaemia (WM) and related disorders. Secondary endpoint results do however suggest that treatment with fludarabine may lead to a longer progression-free survival, and possibly a longer overall survival in patients with WM. The authors note that WM, non-mucosa-associated lymphoid tissue (MALT) marginal zone lymphoma (MZL), and lymphoplasmacytic lymp...
Source: NeLM - News - December 17, 2012 Category: Drugs & Pharmacology Source Type: news
In Waldenstrm macroglobulinemia, fludarabine yields better survival than chlorambucil
NEW YORK (Reuters Health) - Fludarabine improves survival compared with chlorambucil in patients with Waldenstrm macroglobulinemia (WM) and related disorders, according to the multicenter WM1 study. (Source: Modern Medicine)
Source: Modern Medicine - December 14, 2012 Category: Journals (General) Source Type: news
Serous Macular Detachment in Waldenström Macroglobulinemia: A Report of Four Cases
Conclusion: Discontinuity of the outer retina within the macular detachment may enable immunoglobulins along with accumulated intraretinal fluid to flow into the subretinal space, creating a serous retinal detachment. Even with systemic treatment of the underlying Waldenström macroglobulinemia, the visual prognosis was guarded. (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - December 4, 2012 Category: Opthalmology Authors: Paul S. Baker, Sunir J. Garg, Mitchell S. Fineman, Allen Chiang, Rayan A. Alshareef, Jonathan Belmont, Gary C. Brown Tags: Original Articles Source Type: research
CD200 Expression in Plasma Cells of Nonmyeloma Immunoproliferative Disorders: Clinicopathologic Features and Comparison With Plasma Cell Myeloma.
Abstract The majority of plasma cell myelomas (PCMs) are positive for CD200, a membrane protein with immunosuppressive function. There are no flow cytometry data in the literature on plasma cell CD200 expression in other immunoproliferative disorders. Therefore we used flow cytometry to study the expression of CD200 on plasma cells in diagnostic bone marrow aspirates from 61 patients with monoclonal gammopathy of undetermined significance (MGUS) and 10 patients with lymphoplasmacytic lymphoma (LPL). For comparison, we evaluated CD200 expression in 74 PCM bone marrow biopsies. Thirty-three (54.1%) of 61 MGUS cases a...
Source: American Journal of Clinical Pathology - December 1, 2012 Category: Pathology Authors: Olteanu H, Harrington AM, Kroft SH Tags: Am J Clin Pathol Source Type: research
Failure of mefloquine therapy in progressive multifocal leukoencephalopathy: Report of two Japanese patients without human immunodeficiency virus infection
We report on the failure of mefloquine therapy in two Japanese patients with PML unrelated to human immunodeficiency virus. One of the patients was a 47-year-old male who had been treated with chemotherapy for Waldenström macroglobulinemia, and the other was an 81-year-old male with idiopathic CD4+ lymphocytopenia. Diagnosis of PML was established based on MRI findings and increased JC virus DNA in the cerebrospinal fluid in both patients. Mefloquine was initiated about 5months and 2months after the onset of PML, respectively. During mefloquine therapy, clinical and radiological progression was observed, and JC virus DNA ...
Source: Journal of the Neurological Sciences - November 26, 2012 Category: Neurology Authors: Zen Kobayashi, Miho Akaza, Yoshiyuki Numasawa, Shoichiro Ishihara, Hiroyuki Tomimitsu, Kazuo Nakamichi, Masayuki Saijo, Tomohiro Morio, Norio Shimizu, Nobuo Sanjo, Shuzo Shintani, Hidehiro Mizusawa Tags: Short Communications Source Type: research
Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop
This report represents a further update of the consensus panel criteria for the assessment of clinical response in patients with Waldenström macroglobulinaemia (WM). These criteria have been updated in light of further data demonstrating an improvement in categorical responses with new drug regimens as well as acknowledgement of the fact that such responses are predictive of overall outcome. A number of key changes are proposed but challenges do however remain and these include the variability in kinetics of immunoglobulin M (IgM) reduction with different treatment modalities and the apparent discrepancy between IgM and b...
Source: British Journal of Haematology - November 15, 2012 Category: Hematology Authors: Roger G. Owen, Robert A. Kyle, Marvin J. Stone, Andy C. Rawstron, Veronique Leblond, Giampaolo Merlini, Ramon Garcia‐Sanz, Enrique M. Ocio, Enrica Morra, Pierre Morel, Kenneth C. Anderson, Christopher J. Patterson, Nikhil C. Munshi, Alessandra Tedeschi, Tags: Research Paper Source Type: research
Immunotactoid glomerulopathy: clinicopathologic and proteomic study
Conclusions Hematologic malignancy, particularly lymphoma, is not uncommon in ITG. ITG appears to have a better prognosis than other paraprotein-related renal lesions, with a half of patients expected to recover kidney function with immunosuppressive therapy or chemotherapy. The proteomic profile of ITG is consistent with deposition of monotypic immunoglobulins and activation of the classical and terminal pathway of complement. (Source: Nephrology Dialysis Transplantation)
Source: Nephrology Dialysis Transplantation - November 9, 2012 Category: Urology & Nephrology Authors: Nasr, S. H., Fidler, M. E., Cornell, L. D., Leung, N., Cosio, F. G., Sheikh, S. S., Amir, A. A., Vrana, J. A., Theis, J. D., Dogan, A., Sethi, S. Tags: Chronic Kidney Disease Source Type: research
Waldenström's macroglobulinaemia presenting with nephrotic syndrome.
Abstract No abstract available. PMID: 23123536 [PubMed - as supplied by publisher] (Source: The Netherlands Journal of Medicine)
Source: The Netherlands Journal of Medicine - November 1, 2012 Category: Journals (General) Authors: Swaneveld FH, van Dorp WT, Visser O, de Klerk G Tags: Neth J Med Source Type: research
IL-21 in the bone marrow microenvironment contributes to IgM secretion and proliferation of malignant cells in Waldenstrom macroglobulinemia
We report here on the presence of IL-21 in the bone marrow of patients with WM and have identified activated T cells as the source of this cytokine. We readily detected the IL-21 receptor on malignant WM B cells and show that IL-21 significantly increases both IgM secretion and cellular proliferation of these cells with no effect on viability. IL-21 rapidly induces phosphorylation of STAT3 in WM cells, and treatment of the WM cell line MWCL-1 with a STAT3 inhibitor abolished the IL-21–mediated increases in cellular proliferation and IgM secretion. IL-21 also increased the expression of known STAT3 targets involved in...
Source: Blood - November 1, 2012 Category: Hematology Authors: Hodge, L. S., Ziesmer, S. C., Yang, Z. Z., Secreto, F. J., Gertz, M. A., Novak, A. J., Ansell, S. M. Tags: Lymphoid Neoplasia Source Type: research
Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenstrom macroglobulinemia
Acquired von Willebrand syndrome is described in patients with Waldenström macroglobulinemia (WM). Assessment of ristocetin cofactor activity (VWF:RCo) and von Willebrand factor (VWF) antigen (VWF:Ag) in 72 consecutive patients with WM showed a negative relation between VWF levels < 130 U/dL and both monoclonal immunoglobulin M concentration (mIgMC) and viscosity. Ten patients with VWF:RCo < 50 U/dL (< 40 for patients with blood group O) fulfilled the acquired von Willebrand syndrome criteria. They had higher mIgMC and viscosity. Reduction in mIgMC was associated with increase in VWF levels. The low VWF:RCo/V...
Source: Blood - October 18, 2012 Category: Hematology Authors: Hivert, B., Caron, C., Petit, S., Charpy, C., Fankam-Siaka, C., Lecocq, S., Zawadzki, C., Susen, S., Rusu, M., Duhamel, A., Tournilhac, O., Goudemand, J., Morel, P. Tags: Free Research Articles, Lymphoid Neoplasia, Clinical Trials and Observations Source Type: research
Absence of TCL1A expression is a useful diagnostic feature in splenic marginal zone lymphoma
Abstract Splenic marginal zone lymphoma (SMZL) is a low-grade lymphoma showing a rather nonspecific immunophenotype. Gene expression profiling studies suggested that TCL1A could be a marker of SMZL, but reported data are conflicting. We evaluated TCL1A expression in a series of spleen and bone marrow samples involved by SMZL and correlated the findings with other immunophenotypical, morphological, and clinical data. In addition, we evaluated the expression of TCL1A in a series of spleens and lymph nodes involved by lymphomas that might mimic SMZL (13 nodal marginal zone lymphomas (NMZL), 39 follicular lympho...
Source: Virchows Archiv - October 13, 2012 Category: Pathology Tags: Virchows Archiv Source Type: research
Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenstrom macroglobulinemia.
Conclusions. The cytogenetic profile of Waldenström macroglobulinemia thus appears to differ from that of other B-cell lymphomas. Chromosomal abnormalities may help with diagnosis and prognostication, in conjunction with other clinical and biological characteristics. The trial is registered with Clinicaltrials.gov, numbers NCT00566332 and NCT00608374. PMID: 23065509 [PubMed - as supplied by publisher] (Source: Haematologica)
Source: Haematologica - October 12, 2012 Category: Hematology Authors: Nguyen-Khac F, Lambert J, Chapiro E, Grelier A, Mould S, Barin C, Daudignon A, Gachard N, Struski S, Henry C, Penther D, Mossafa H, Andrieux J, Eclache V, Bilhou-Nabera C, Luquet I, Terre C, Baranger L, Mugneret F, Chiesa J, Mozziconacci MJ, Callet-Bauchu Tags: Haematologica Source Type: research
Patterns of survival in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia: A population‐based study of 1,555 patients diagnosed in Sweden from 1980 to 2005
Abstract Clinical management of lymphoplasmacytic lymphoma (LPL)/Waldenström macroglobulinemia (WM) has changed considerably over recent years, reflected in the use of new therapeutic agents (purine analogues, monoclonal antibodies, thalidomide‐ and bortezomib‐based therapies). No population‐based studies and few randomized trials have been performed to assess survival in newly diagnosed LPL/WM. We performed a large population‐based study in Sweden including 1,555 LPL/WM patients diagnosed 1980 to 2005. Relative survival ratios (RSR) and excess mortality rate ratios (EMRR) were computed as measures of survival. Su...
Source: American Journal of Hematology - October 11, 2012 Category: Hematology Authors: Sigurdur Y Kristinsson, Sandra Eloranta, Paul W Dickman, Therese M‐L Andersson, Ingemar Turesson, Ola Landgren, Magnus Björkholm Tags: Research Article Source Type: research
Mechanisms of activity of the TORC1 inhibitor everolimus in Waldesntrom's macroglobulinemia.
CONCLUSIONS: These findings provide a better understanding of the mechanisms that are responsible for everolimus-induced anti-WM activity. PMID: 23048077 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 9, 2012 Category: Cancer & Oncology Authors: Roccaro AM, Sacco A, Jia X, Banwit R, Maiso P, Azab F, Ludmila F, Manier S, Azab AK, Ghobrial IM Tags: Clin Cancer Res Source Type: research
IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas
IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas Leukemia advance online publication, October 5 2012. doi:10.1038/leu.2012.257 Authors: N Gachard, M Parrens, I Soubeyran, B Petit, A Marfak, D Rizzo, M Devesa, M Delage-Corre, V Coste, M P Laforêt, A de Mascarel, J P Merlio, K Bouabdhalla, N Milpied, P Soubeyran, A Schmitt, D Bordessoule, M Cogné & J Feuillard (Source: Leukemia)
Source: Leukemia - October 5, 2012 Category: Hematology Authors: N GachardM ParrensI SoubeyranB PetitA MarfakD RizzoM DevesaM Delage-CorreV CosteM P LaforêtA de MascarelJ P MerlioK BouabdhallaN MilpiedP SoubeyranA SchmittD BordessouleM CognéJ Feuillard Tags: marginal zone lymphoma immunoglobulin gene sequence MYD88 Source Type: research
Steroid-resistant minimal change nephrotic syndrome in Waldenström macroglobulinemia
Content Type Journal ArticleCategory Letter to the EditorPages 1-2DOI 10.1007/s00277-012-1586-zAuthors Johnny Sayegh, LUNAM Université, Angers, FranceVirginie Boisliveau, LUNAM Université, Angers, FranceFrançoise Boyer, Service des maladies du Sang, CHU Angers, Angers, FranceCaroline Savary, LUNAM Université, Angers, FranceFrançois Beloncle, LUNAM Université, Angers, FranceJean-François Augusto, LUNAM Université, Angers, France Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (Source: Annals of Hematology)
Source: Annals of Hematology - October 3, 2012 Category: Hematology Tags: Annals of Hematology Source Type: research
Results of surgical resection for patients with thymoma according to World Health Organization histology and Masaoka staging.
CONCLUSIONS: Long-term survival can be expected not only for patients at early stages, as well as for patients with stages III and IV disease if surgical resection is completed macroscopically. PMID: 23063086 [PubMed - in process] (Source: Asian Journal of Surgery)
Source: Asian Journal of Surgery - October 1, 2012 Category: Surgery Authors: Shinohara S, Hanagiri T, So T, Yasuda M, Takenaka M, Nagata Y, Shimokawa H, Nakagawa M, Uramoto H, So T, Tanaka F Tags: Asian J Surg Source Type: research
A diagnostic mystery solved by electron microscopy: a case of an "atypical" lymphoproliferative disorder.
This report illustrates how electron microscopy can be used as a valuable additional diagnostic tool in difficult cases. PMID: 23025654 [PubMed - in process] (Source: Ultrastructural Pathology)
Source: Ultrastructural Pathology - October 1, 2012 Category: Pathology Authors: Lee S, Graham LM, Chan G, Ruskova A Tags: Ultrastruct Pathol Source Type: research
Reappraising the role of autologous transplantation for indolent B-cell lymphomas in the chemoimmunotherapy era: is it still relevant?
Reappraising the role of autologous transplantation for indolent B-cell lymphomas in the chemoimmunotherapy era: is it still relevant? Bone Marrow Transplantation advance online publication, September 24 2012. doi:10.1038/bmt.2012.182 Author: M Hamadani (Source: Bone Marrow Transplantation)
Source: Bone Marrow Transplantation - September 24, 2012 Category: Hematology Authors: M Hamadani Tags: follicular lymphoma mantle cell lymphoma Waldenström macroglobulinemia autologous transplantation second malignancies Source Type: research
When an Incurable Cancer Meets a New Genetic TargetWhen an Incurable Cancer Meets a New Genetic Target
Dr. Maurie Markman looks at the broader implications of finding a single genetic mutation in 90% of patients with Waldenström macroglobulinemia. Medscape Hematology-Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 14, 2012 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news
CD86+ or HLA-G+ can be transferred via trogocytosis from myeloma cells to T cells and are associated with poor prognosis
The transfer of membrane proteins between cells during contact, known as trogocytosis, can create novel cells with a unique phenotype and altered function. We demonstrate that trogocytosis is more common in multiple myeloma (MM) than chronic lymphocytic leukemia and Waldenstrom macroglobulinaemia; that T cells are more probable to be recipients than B or natural killer cells; that trogocytosis occurs independently of either the T-cell receptor or HLA compatibility; and that after trogocytosis, T cells with acquired antigens can become novel regulators of T-cell proliferation. We screened 168 patients with MM and found that...
Source: Blood - September 6, 2012 Category: Hematology Authors: Brown, R., Kabani, K., Favaloro, J., Yang, S., Ho, P. J., Gibson, J., Fromm, P., Suen, H., Woodland, N., Nassif, N., Hart, D., Joshua, D. Tags: Lymphoid Neoplasia Source Type: research
Severe Heart Failure after Bortezomib Treatment in a Patient with Multiple Myeloma: A Case Report and Review of the Literature.
Conclusion: We reviewed the possible mechanisms involved in cardiotoxicity caused by bortezomib, and the diagnostic methods and importance of early identification of this adverse event. Differential diagnoses such as cardiac amyloidosis and viral myocarditis are also discussed. To our knowledge, this is the first case where pericardial effusion and mitral regurgitation were described after bortezomib treatment. PMID: 22964848 [PubMed - as supplied by publisher] (Source: Acta Haematologica)
Source: Acta Haematologica - September 4, 2012 Category: Hematology Authors: Bockorny M, Chakravarty S, Schulman P, Bockorny B, Bona R Tags: Acta Haematol Source Type: research
Mutation Linked to Rare Lymphoma (CME/CE)
(MedPage Today) -- A genetic mutation in patients with Waldenstrom's macroglobulinemia has been identified and may have implications for diagnosis and treatment of this lymphoplasmacytic lymphoma, researchers reported. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - August 29, 2012 Category: Hematology Source Type: news
MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia
New England Journal of Medicine, Volume 367, Issue 9, Page 826-833, August 2012. (Source: New England Journal of Medicine)
Source: New England Journal of Medicine - August 29, 2012 Category: Internal Medicine Tags: article Source Type: research
TG Therapeutics, Inc. Announces Poster Presentation for Ublituximab (TGTX-1101) at the 7th International Workshop on Waldenstrom's Macroglobulinemia
NEW YORK, Aug. 24, 2012 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (OTCBB:TGTX) today announced a poster presentation at the 7th International Workshop on Waldenstrom's Macroglobulinemia (WM), held in Newport, RI. The poster entitled "Role of NK-mediated ADCC in Waldenstrom's Macroglobulinemia Patients: Evidence Supporting a Therapeutic Strategy" was presented by Professor Veronique Leblond, MD, PhD, Head of Hematology, Hospital Pitie-Salpetriere, Paris, France. Ublituximab, a novel, third generation chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen, has been bioengineered for enhanced biological a...
Source: Medical News (via PRIMEZONE) - August 24, 2012 Category: Pharmaceuticals Source Type: news
Central and peripheral nervous system immune mediated demyelinating disease after allogeneic hemopoietic stem cell transplantation for hematologic disease
Abstract Immune mediated demyelinating disease (IMDD) after allogeneic hemopoietic stem cell transplant (HSCT) is rare and its etiology unclear. In this retrospective study, we identified patients who underwent HSCT between January 1992 and December 2010 and had IMDD post transplant. A total of 1,484 patients received HSCT and 7 (0.5 %) suffered from IMDD; five were men, and the median age was 54 years (range, 29–64 years). HSCT treated acute myeloid leukemia (n = 5), myelodysplastic syndrome (n = 1), and Waldenström macroglobulinemia (n = 1). All received an H...
Source: Journal of Neuro-Oncology - August 23, 2012 Category: Cancer & Oncology Tags: Journal of Neuro-Oncology Source Type: research
LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas
miR-155 acts as an oncogenic miR in B-cell lymphoproliferative disorders, including Waldenstrom macroglobulinemia (WM) and chronic lymphocytic leukemia, and is therefore a potential target for therapeutic intervention. However, efficient targeting of miRs in tumor cells in vivo remains a significant challenge for the development of miR-155–based therapeutics for the treatment of B-cell malignancies. In the present study, we show that an 8-mer locked nucleic acid anti–miR-155 oligonucleotide targeting the seed region of miR-155 inhibits WM and chronic lymphocytic leukemia cell proliferation in vitro. Moreover, a...
Source: Blood - August 23, 2012 Category: Hematology Authors: Zhang, Y., Roccaro, A. M., Rombaoa, C., Flores, L., Obad, S., Fernandes, S. M., Sacco, A., Liu, Y., Ngo, H., Quang, P., Azab, A. K., Azab, F., Maiso, P., Reagan, M., Brown, J. R., Thai, T.-H., Kauppinen, S., Ghobrial, I. M. Tags: Lymphoid Neoplasia Source Type: research
Excellent long-term survival of 170 patients with Waldenström’s macroglobulinemia treated in private oncology practices and a university hospital
Abstract The purpose of this study was to compare treatment and outcome of patients with Waldenström’s macroglobulinemia (WM) in four private oncology practices (PP) and a university hospital (UH) in southwest Germany. We retrospectively reviewed the charts of all patients with WM of the last two decades of four PP in Mannheim, Heidelberg, Karlsruhe, and Speyer and the Department of Hematology of the University of Heidelberg. One hundred seventy patients could be identified, 74 from PP, 96 from the UH. Median age was 63.3 years. Patients from PP were older (median 65.3 vs. 62.5 years, p = 0....
Source: Annals of Hematology - August 16, 2012 Category: Hematology Tags: Annals of Hematology Source Type: research
Occurrence of lymphoplasmacytic lymphoma 6 years after amelioration of primary cold agglutinin disease by rituximab therapy.
Abstract Cold agglutinin disease (CAD) is a rare autoimmune hemolytic anemia, classified into primary and secondary types. Secondary CAD accompanies infection or malignant disease, most often lymphoma, whereas primary CAD frequently represents a lymphoproliferative bone marrow disorder characterized by clonal expansion of B cells. Here, I describe a case of lymphoplasmacytic lymphoma (LPL) developed 6 years after amelioration of primary CAD by rituximab monotherapy. A 54-year-old Japanese woman was diagnosed with primary CAD characterized by a small fraction of B lymphocytes and kappa laterality in the peripheral ...
Source: International Journal of Hematology - August 11, 2012 Category: Hematology Authors: Tanaka H, Hashimoto S, Sugita Y, Sakai S, Takeda Y, Abe D, Takagi T, Nakaseko C Tags: Int J Hematol Source Type: research
Successful Treatment of γ-Heavy-Chain Disease with Rituximab and Fludarabine.
This report suggests the efficacy of rituximab plus fludarabine therapy for LPL-associated γ-HCD. PMID: 22890122 [PubMed - as supplied by publisher] (Source: Acta Haematologica)
Source: Acta Haematologica - August 10, 2012 Category: Hematology Authors: Inoue D, Matsushita A, Kiuchi M, Takiuchi Y, Nagano S, Arima H, Mori M, Tabata S, Yamashiro A, Maruoka H, Oita T, Imai Y, Takahashi T Tags: Acta Haematol Source Type: research
A multicenter phase II study of single-agent enzastaurin in previously treated Waldenstrom macroglobulinemia.
CONCLUSION: Enzastaurin was active and well tolerated in previously treated patients with WM. Due to the small sample size of this uncontrolled study, further assessment of the relationship between IL-15 and response to enzastaurin in patients with WM is required. These results warrant further investigation of enzastaurin for the treatment of WM. PMID: 22879385 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - August 9, 2012 Category: Cancer & Oncology Authors: Ghobrial IM, Moreau P, Harris B, Poon T, Jourdan E, Maisonneuve HM, Benhadji KA, Hossain A, Nguyen T, Wooldridge JE, Leblond V Tags: Clin Cancer Res Source Type: research
Familial aggregation of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia with solid tumors and myeloid malignancies.
Abstract Lymphoplasmacytic lymphoma (LPL)/Waldenström macroglobulinemia (WM) is a B-cell disorder resulting from the accumulation, predominantly in the bone marrow, of clonally related lymphoplasmacytic cells. LPL/WM is a very rare disease, with an incidence rate of 3-4 cases per million people per year.Currently, the causes of LPL/WM are poorly understood; however, there are emerging data to support a role for immune-related factors in the pathogenesis of LPL/WM. In addition, data show that genetic factors are of importance in the etiology of LPL/WM. In this paper, we will review the current knowledge about famil...
Source: Acta Haematologica - August 8, 2012 Category: Hematology Authors: Kristinsson SY, Goldin LR, Turesson I, Björkholm M, Landgren O Tags: Acta Haematol Source Type: research
Gamma heavy chain disease in a patient with underlying lymphoplasmacytic lymphoma of the thyroid. Report of a case and comparison with other reported cases with thyroid involvement.
CONCLUSION: Gamma heavy chain disease has a protean manifestation; however there appears to be a more uniform pattern of the disease when it is associated with the thyroid. The inclusion of protein studies in cases diagnosed with chronic thyroiditis by FNA may aid in establishing γ heavy chain disease with underlying thyroid involvement. In this case serum and urine electrophoresis, and immunofixation studies which are simple and affordable tests facilitated the hematologic workup and follow up. PMID: 22561184 [PubMed - in process] (Source: International Journal of Clinical Chemistry)
Source: International Journal of Clinical Chemistry - August 1, 2012 Category: Chemistry Authors: Tan JN, Kroll MH, O'Hara CJ, Everett PC, Erdogan E Tags: Clin Chim Acta Source Type: research
Ofatumumab, the first human anti‐CD20 monoclonal antibody for the treatment of B cell hematologic malignancies
Ofatumumab is the first human anti‐CD20 monoclonal antibody to be approved for patients in the United States and the European Union. Ofatumumab received accelerated approval from the U.S. Food and Drug Administration in October 2009 and was granted a conditional marketing authorization by the European Medicines Agency in April 2010 for the treatment of patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab, based on interim results of a pivotal phase 2 trial. Preliminary positive results for ofatumumab in combination with chemotherapy in patients with CLL are currently being confirmed ...
Source: Annals of the New York Academy of Sciences - July 25, 2012 Category: Science Authors: Ira V. Gupta, Roxanne C. Jewell Source Type: research
Cutaneous macroglobulinosis: a case series
We present a series of three patients with cutaneous macroglobulinosis and explore variations in the clinical and histopathological findings of this uncommon entity. (Source: Journal of Cutaneous Pathology)
Source: Journal of Cutaneous Pathology - July 18, 2012 Category: Pathology Authors: Brendan J. Camp, Cynthia M. Magro Tags: Case Report Source Type: research
Molecular pathogenesis of Waldenstrom macroglobulinemia.
Abstract Waldenström macroglobulinemia is an indolent, lymphoproliferative disease, characterized by a heterogeneous lymphoplasmacytic bone marrow infiltrate and high immunoglobulin M production. While technological advances over the past several decades have dramatically improved the ability to study the molecular basis of Waldenström macroglobulinemia, the pathogenesis basis of the disease remains fragmented. Undoubtedly there has been success in uncovering underlying aberrations and deregulated mechanisms in this disease and provide useful information for identifying biomarkers for disease diagnosis, risk stra...
Source: Haematologica - July 6, 2012 Category: Hematology Authors: Braggio E, Philipsborn C, Novak A, Hodge L, Ansell S, Fonseca R Tags: Haematologica Source Type: research
Cast Nephropathy and Light-Chain Deposition Disease in Waldenström Macroglobulinemia
We report the occurrence of cast nephropathy associated with light-chain deposition disease in 2 patients with Waldenström macroglobulinemia, which resulted in severe and prolonged kidney failure. (Source: American Journal of Kidney Diseases)
Source: American Journal of Kidney Diseases - June 21, 2012 Category: Urology & Nephrology Authors: Viviane Gnemmi, Xavier Leleu, François Provot, Florence Moulonguet, David Buob Tags: Kidney Biopsy Teaching Case Source Type: research
Mini-report: Microcirculatory flow abnormalities in a patient with severe hyperviscosity syndrome.
Abstract A 60-year women was admitted to ICU because seizures, poor peripheral perfusion and acute renal failure. In laboratory tests an hyperproteinemia was detected, and therefore an electrophoresis and a bone marrow biopsy were performed, confirming a WaldenstrÃÂ¶m Macroglobulinemia with severe hyperviscosity. Sublingual microcirculation was assessed with videomicroscopy, finding sluggish and intermittent microvascular flow, despite normal lactate and mixed venous O2 saturation. Promptly plasmapheresis was started, with viscosity decrease in parallel with improvement in microvascular flow and clinical statu...
Source: Clinical Hemorheology and Microcirculation - June 18, 2012 Category: Hematology Authors: Ruiz C, Hernandez G, Andresen M, Ince C, Bruhn A Tags: Clin Hemorheol Microcirc Source Type: research
Follicular lymphoma with prominent Dutcher body formation: a pathologic study of 3 cases in comparison with nodal or splenic lymphoplasmacytic lymphoma and marginal zone lymphoma
We report a pathologic study of 3 cases of follicular lymphoma with extensive Dutcher body formation in comparison with lymphoplasmacytic lymphoma and marginal zone lymphoma. Of 3 cases, 1 showed a follicular growth pattern, whereas the other 2 cases demonstrated only a vague nodular appearance highlighted by immunohistochemical analysis. Cells containing Dutcher bodies were counted at 25, 90, or 110 per high-power field in each case, respectively. In 2 cases, cells with Dutcher bodies were clustered in an intrafollicular distribution, a possible histopathologic clue for follicular lymphoma. Immunoglobulin M κ was identif...
Source: Human Pathology - May 21, 2012 Category: Pathology Authors: Endi Wang, Maggie Stoecker, James Burchette, Catherine Rehder Tags: Original Contributions Source Type: research
Lymphoma Vaccine Therapy: Next Steps After a Positive, Controlled Phase III Clinical Trial
Many of the efforts toward developing vaccines against human malignancies have been frustrated by the lack of identification of a tumor-specific antigen that would allow tumor cells to be distinguished from normal cells. Idiotypic determinants of the surface immunoglobulin (Ig) associated with a given patient's B-cell lymphoma are unique to that tumor, and can thus serve as a tumor-specific marker. When conjugated to the immune carrier keyhole limpet hemocyanin (KLH), vaccination with an idiotype protein vaccine has been able to improve length of freedom from disease relapse in patients with follicular lymphoma (FL) in a m...
Source: Seminars in Oncology - May 16, 2012 Category: Cancer & Oncology Authors: Sheeba K. Thomas, Larry W. Kwak Tags: Section I: Clinical Investigations in a Specific Cancer Type Source Type: research